There are currently 50 clinical trials in Deland, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Avail Clinical Research, LLC, GSK Investigational Site, Avail Clinical Research and Pfizer Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
NCT04899336
Recruiting
The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placebo in the prevention of the first invasive extraintestinal pathogenic Escherichia coli disease (IED) event caused by ExPEC9V O-serotypes.
Gender:
All
Ages:
60 years and above
Trial Updated:
04/23/2024
Locations: Accel Research Sites, DeLand, Florida
Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Register for Updates
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383
Recruiting
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), n... Read More
Gender:
All
Ages:
Between 40 years and 79 years
Trial Updated:
04/23/2024
Locations: Hillcrest Medical Research, DeLand, Florida
Conditions: Primary Prevention of Atherosclerotic Cardiovascular Disease
Register for Updates
Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury
NCT05171673
Recruiting
A multi-center, prospective, open-label, controlled study of the pharmacokinetics and safety of the LicartTM topical system in pediatric and adult participants with minor soft tissue injuries. 150 male and female participants aged 6-16 and 18-45 with soft tissue injuries meeting the following criteria will be enrolled to evaluate the pharmacokinetics and safety of the Licart topical system in pediatric and adult participants with minor soft tissue injuries over a 14-day treatment course. The ana... Read More
Gender:
All
Ages:
Between 6 years and 45 years
Trial Updated:
04/22/2024
Locations: University Clinical Research - Deland, LLC, DeLand, Florida
Conditions: Soft Tissue Injuries
Register for Updates
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
NCT06122077
Recruiting
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).
Gender:
All
Ages:
50 years and above
Trial Updated:
04/19/2024
Locations: Hillcrest Medical Research, DeLand, Florida
Conditions: Lung Cancer Diagnosis
Register for Updates
Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome
NCT06285214
Recruiting
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Accel Research Sites, DeLand, Florida
Conditions: Interstitial Cystitis/Bladder Pain Syndrome
Register for Updates
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
NCT04320342
Recruiting
The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.
Gender:
All
Ages:
40 years and above
Trial Updated:
04/17/2024
Locations: Chiesi Clinical Trial Site 840133, DeLand, Florida
Conditions: COPD, COPD Exacerbation
Register for Updates
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
NCT05372419
Recruiting
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/15/2024
Locations: Accel Research Sites, DeLand, Florida
Conditions: Atopic Dermatitis
Register for Updates
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
NCT05971940
Recruiting
The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Hillcrest Medical Research, DeLand, Florida
Conditions: Type 2 Diabetes
Register for Updates
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
NCT06361875
Recruiting
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), QIV- high dose (HD) [adults ≥ 65 years of age only], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: Accel Clinical Research-Deland Clinical Research Unit Site Number : 8400001, DeLand, Florida
Conditions: Influenza Immunization
Register for Updates
Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis
NCT05891119
Recruiting
The primary objective of the study is to evaluate the pharmacokinetics (PK) of multiple cytochrome P450 (CYP450) substrates alone and in combination with rocatinlimab in participants with moderate to severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/10/2024
Locations: Accel Research Sites (ACR), DeLand, Florida
Conditions: Atopic Dermatitis
Register for Updates
Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
NCT05763875
Recruiting
CKJX839D12304 is a research study to determine if the study treatment, called inclisiran, in comparison to placebo or ezetimibe can effectively reduce LDL-C as measured by percentage change from baseline to Day 150. This study is being conducted in eligible participants with primary hypercholesterolemia not receiving any lipid-lowering therapy (LLT), with a 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk of less than 7.5%.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/09/2024
Locations: Hillcrest Medical Research, DeLand, Florida
Conditions: Hypercholesterolemia
Register for Updates
To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis
NCT04684485
Recruiting
This is a Phase II, randomized, double-blind, placebo-controlled study in subjects with moderate to severe atopic dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Site # 30, DeLand, Florida
Conditions: Dermatitis, Atopic
Register for Updates